- Home
- CCIF vs STTK Comparison
CCIF vs STTK Comparison
Compare CCIF & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIF
- STTK
- Stock Information
- Founded
- CCIF 2011
- STTK 2016
- Country
- CCIF United States
- STTK United States
- Employees
- CCIF N/A
- STTK N/A
- Industry
- CCIF Finance/Investors Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- CCIF Finance
- STTK Health Care
- Exchange
- CCIF Nasdaq
- STTK Nasdaq
- Market Cap
- CCIF 110.4M
- STTK 112.6M
- IPO Year
- CCIF N/A
- STTK 2020
- Fundamental
- Price
- CCIF $5.17
- STTK $1.91
- Analyst Decision
- CCIF
- STTK Hold
- Analyst Count
- CCIF 0
- STTK 5
- Target Price
- CCIF N/A
- STTK $3.00
- AVG Volume (30 Days)
- CCIF 76.9K
- STTK 144.6K
- Earning Date
- CCIF 01-01-0001
- STTK 11-06-2025
- Dividend Yield
- CCIF 25.90%
- STTK N/A
- EPS Growth
- CCIF N/A
- STTK N/A
- EPS
- CCIF N/A
- STTK N/A
- Revenue
- CCIF N/A
- STTK $1,000,000.00
- Revenue This Year
- CCIF N/A
- STTK N/A
- Revenue Next Year
- CCIF N/A
- STTK N/A
- P/E Ratio
- CCIF N/A
- STTK N/A
- Revenue Growth
- CCIF N/A
- STTK N/A
- 52 Week Low
- CCIF $7.43
- STTK $0.69
- 52 Week High
- CCIF $10.16
- STTK $2.71
- Technical
- Relative Strength Index (RSI)
- CCIF 37.21
- STTK 47.96
- Support Level
- CCIF $5.13
- STTK $1.86
- Resistance Level
- CCIF $5.27
- STTK $2.06
- Average True Range (ATR)
- CCIF 0.09
- STTK 0.15
- MACD
- CCIF 0.01
- STTK -0.01
- Stochastic Oscillator
- CCIF 19.23
- STTK 53.52
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.